16d
Pharmaceutical Technology on MSNMedigene and EpimAb to develop T cell engagers for solid tumoursMedigene and EpimAb Biotherapeutics have signed a co-development agreement involving T cell receptor (TCR)-guided T cell ...
Unlike CAR-T therapy, which is limited to surface antigens, TCR therapy can recognize intracellular tumor-associated antigens presented by major histocompatibility complex (MHC) molecules, expanding ...
TScan Therapeutics is developing TSC-101 and multiplex TCR-Ts for cancer treatment. See why TCRX stock holds potential with ...
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor ...
engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of ...
“For the PLEXI-T™ solid tumor program, we continue to enroll patients investigating seven different TCR-Ts, including the recently added MAGE-A4 TCR-T (TSC-202-A0201). We look forward to ...
EpimAb_LogoPlanegg/Martinsried and Shanghai, February 27, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, ...
The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent ...
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer ...
Bispecific TCR-TCEs offer a promising solution, leveraging the body’s immune system to target and eradicate cancer cells with heightened precision. The market for these therapies is projected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results